TriangleLABELS · 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
HADLIMA
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-05-14
- Captured
- 2026-09-09T23:37:51.659493+00:00
- Current indication reconciliation
- Not reconciled
Boxed warning in this label
- WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HADLIMA if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HADLIMA use and during therapy. Initiate treatment for latent TB prior to HADLIMA use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with HADLIMA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 )] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )] . WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. • Discontinue HADLIMA if a patient develops a serious infection or sepsis during treatment. • Perform test for latent TB; if positive, start treatment for TB prior to starting HADLIMA. • Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. • Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HADLIMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HADLIMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
Full extracted label fields
- application numbers
- BLA761059
- boxed warning exact
- WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HADLIMA if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HADLIMA use and during therapy. Initiate treatment for latent TB prior to HADLIMA use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with HADLIMA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HADLIMA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 )] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )] . WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. • Discontinue HADLIMA if a patient develops a serious infection or sepsis during treatment. • Perform test for latent TB; if positive, start treatment for TB prior to starting HADLIMA. • Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. • Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
- brand names
- HADLIMA
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c361dd60-c88d-4f3c-b98c-79687bbc3450
- generic names
- ADALIMUMAB-BWWD
- id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- indications and usage exact
- 1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HADLIMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HADLIMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
- indications and usage tables exact
- is original packager
- manufacturer names
- A-S Medication Solutions
- matched search terms
- tumor
- package ndcs
- 50090-6707-0
- product ndcs
- 50090-6707
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Warnings and Precautions, Autoimmunity ( 5.9 ) 10/2025
- record type
- complete_spl_indications_section_candidate
- routes
- SUBCUTANEOUS
- rxcuis
- 2640430
- 2640432
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00400.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 400
- total
- 830
- sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl effective time
- 20260514
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- substance names
- ADALIMUMAB
- uniis
- FYS6T7F842
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
- not_identified_as_original_packager
Drugs@FDA application source records
- application number
- BLA761059
- payload
- all indexed label documents
- Appl No
- 761059
- Application Docs Date
- 2019-07-23 00:00:00
- Application Docs ID
- 59432
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 761059
- Application Docs Date
- 2022-06-21 00:00:00
- Application Docs ID
- 71412
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761059s004lbl.pdf
- Submission No
- 4
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2022-08-17 00:00:00
- Application Docs ID
- 71825
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761059s005lbl.pdf
- Submission No
- 5
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2023-01-03 00:00:00
- Application Docs ID
- 73068
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761059Orig1s007lbl.pdf
- Submission No
- 7
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2023-04-27 00:00:00
- Application Docs ID
- 74096
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761059Orig1s013lbl.pdf
- Submission No
- 13
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2023-06-27 00:00:00
- Application Docs ID
- 74630
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761059s006lbl.pdf
- Submission No
- 6
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2023-07-12 00:00:00
- Application Docs ID
- 74725
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761059s008lbl.pdf
- Submission No
- 8
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2024-07-02 00:00:00
- Application Docs ID
- 78961
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761059s018lbl.pdf
- Submission No
- 18
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2025-05-21 00:00:00
- Application Docs ID
- 82224
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761059s025s026lbl.pdf
- Submission No
- 25
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2025-05-21 00:00:00
- Application Docs ID
- 82225
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761059s025s026lbl.pdf
- Submission No
- 26
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2025-06-24 00:00:00
- Application Docs ID
- 82647
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761059s030lbl.pdf
- Submission No
- 30
- Submission Type
- SUPPL
- Appl No
- 761059
- Application Docs Date
- 2025-10-20 00:00:00
- Application Docs ID
- 83823
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761059s032lbl.pdf
- Submission No
- 32
- Submission Type
- SUPPL
- all submission records
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 15
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2019-07-23 00:00:00
- Submission Type
- ORIG
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 4
- Submission Status
- AP
- Submission Status Date
- 2022-06-17 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 5
- Submission Status
- AP
- Submission Status Date
- 2022-08-15 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 6
- Submission Status
- AP
- Submission Status Date
- 2023-06-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 7
- Submission Status
- AP
- Submission Status Date
- 2022-12-23 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 8
- Submission Status
- AP
- Submission Status Date
- 2023-07-11 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 13
- Submission Status
- AP
- Submission Status Date
- 2023-04-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 28
- Submission No
- 18
- Submission Status
- AP
- Submission Status Date
- 2024-06-28 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- N/A
- Submission Class Code ID
- 6
- Submission No
- 25
- Submission Status
- AP
- Submission Status Date
- 2025-05-21 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- N/A
- Submission Class Code ID
- 6
- Submission No
- 26
- Submission Status
- AP
- Submission Status Date
- 2025-05-21 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 30
- Submission Status
- AP
- Submission Status Date
- 2025-06-23 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761059
- Review Priority
- N/A
- Submission Class Code ID
- 4
- Submission No
- 32
- Submission Status
- AP
- Submission Status Date
- 2025-10-17 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- BLA761059
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761059
- has approved submission record
- true
- latest approved submission date
- 2026-04-29
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 761059
- Application Docs Date
- 2026-05-01 00:00:00
- Application Docs ID
- 85792
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761059s036lbl.pdf
- Submission No
- 36
- Submission Type
- SUPPL
- official application record
- Appl No
- 761059
- Appl Public Notes
- Appl Type
- BLA
- Sponsor Name
- SAMSUNG BIOEPIS CO LTD
- openfda application present
- true
- products
- Active Ingredient
- ADALIMUMAB-BWWD
- Appl No
- 761059
- Drug Name
- HADLIMA
- Form
- INJECTABLE;INJECTION
- Product No
- 001
- Reference Drug
- 0
- Reference Standard
- 0
- Strength
- 40MG/0.8ML
- marketing status
- Prescription
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 286
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-57d1c36d0f1fab9175ec
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-32fb34294af97e9225f6
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 82
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 32
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 86
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 507
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhib
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-d2802ebd966a56103622
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-519ec10623279eef795b
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 250
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 236
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 307
- end exclusive
- true
- exact text
- • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 87
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 3 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 517
- end exclusive
- true
- exact text
- symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 108
- current approval status
- not_reconciled
- duplicate text group
- dup-c0c703c55d19df13dd3d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-96a382268e03900c2e4c
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 317
- end exclusive
- true
- exact text
- ( 1.1 ) .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 308
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 4 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 670
- end exclusive
- true
- exact text
- inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptom
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 118
- current approval status
- not_reconciled
- duplicate text group
- dup-7874bebd5390bde67a67
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-6a94b79dbe68b3d24c5f
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ).
- kind
- age
- polarity
- not_inferred
- span
- end
- 451
- end exclusive
- true
- exact text
- 2 years of age
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 437
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 470
- end exclusive
- true
- exact text
- • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ).
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 318
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 5 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 841
- end exclusive
- true
- exact text
- everely active rheumatoid arthritis. ( 1.1 ) . • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of ag
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 271
- current approval status
- not_reconciled
- duplicate text group
- dup-e835007b437609b3d80e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-e1a173489066be27ef47
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ).
- kind
- age
- polarity
- not_inferred
- span
- end
- 600
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 586
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 641
- end exclusive
- true
- exact text
- • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ).
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 471
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 6 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 933
- end exclusive
- true
- exact text
- rs of age and older ( 1.2 ). • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adu
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 442
- current approval status
- not_reconciled
- duplicate text group
- dup-151d21872171858f5194
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-9a286090b0b53f2ed4b2
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ).
- kind
- age
- polarity
- not_inferred
- span
- end
- 689
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 675
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 733
- end exclusive
- true
- exact text
- • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ).
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 642
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1062
- end exclusive
- true
- exact text
- ructural damage, and improving physical function in adult patients with active psoriatic arthritis ( 1.3 ). • Reducing signs and symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were i
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 534
- current approval status
- not_reconciled
- duplicate text group
- dup-ad5249badf92bccb13bb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-9c63708cdc7e1dd9017e
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) .
- kind
- age
- polarity
- not_inferred
- span
- end
- 804
- end exclusive
- true
- exact text
- adults
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 798
- context exact
- moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) .
- kind
- age
- polarity
- not_inferred
- span
- end
- 827
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 809
- context exact
- ely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) .
- kind
- age
- polarity
- not_inferred
- span
- end
- 842
- end exclusive
- true
- exact text
- 6 years of age
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 828
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 862
- end exclusive
- true
- exact text
- • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 734
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1154
- end exclusive
- true
- exact text
- symptoms in adult patients with active ankylosing spondylitis ( 1.4 ). • Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic pla
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 663
- current approval status
- not_reconciled
- duplicate text group
- dup-2d2987b475360d7236eb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-1e4a16dd7a5f95bd9ba7
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) .
- kind
- age
- polarity
- not_inferred
- span
- end
- 944
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 930
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 954
- end exclusive
- true
- exact text
- • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 863
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · limitation of use
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 1288
- end exclusive
- true
- exact text
- tely to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older ( 1.5 ) . • Treatment of moderately to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriat
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 755
- current approval status
- not_reconciled
- duplicate text group
- dup-0c2162f73930ddd0454c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-66cff7e7b26398d8651e
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1088
- end exclusive
- true
- exact text
- Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 955
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 10 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1490
- end exclusive
- true
- exact text
- to severely active ulcerative colitis in adult patients ( 1.6 ) . Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 889
- current approval status
- not_reconciled
- duplicate text group
- dup-7135d1bf109a51ee5341
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-45934d357832946758ba
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
- kind
- age
- polarity
- not_inferred
- span
- end
- 1118
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1104
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1290
- end exclusive
- true
- exact text
- • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1089
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1500
- end exclusive
- true
- exact text
- Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoi
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1091
- current approval status
- not_reconciled
- duplicate text group
- dup-8fcd868e1f3003d2989f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-f0de816772dcd251f71e
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1300
- end exclusive
- true
- exact text
- ( 1.7 ) .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1291
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1578
- end exclusive
- true
- exact text
- of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing maj
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1101
- current approval status
- not_reconciled
- duplicate text group
- dup-ab84efac5ddacbb93f7a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-fddfa8a5d4c79189820b
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Treatment of moderate to severe hidradenitis suppurativa in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1377
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1363
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1378
- end exclusive
- true
- exact text
- • Treatment of moderate to severe hidradenitis suppurativa in adult patients.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1301
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1588
- end exclusive
- true
- exact text
- didates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinica
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1179
- current approval status
- not_reconciled
- duplicate text group
- dup-5949a7ba42aa2443bd51
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-ae6b1f07a8b8a2ba4753
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1388
- end exclusive
- true
- exact text
- ( 1.8 ) .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1379
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1686
- end exclusive
- true
- exact text
- r systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in ad
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1189
- current approval status
- not_reconciled
- duplicate text group
- dup-af37a5c216b306f166cd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-b0f1ed200a944a4bd6b2
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- f non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) .
- kind
- age
- polarity
- not_inferred
- span
- end
- 1476
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1462
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1486
- end exclusive
- true
- exact text
- • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1389
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1955
- end exclusive
- true
- exact text
- te. ( 1.7 ) . • Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) . • Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients ( 1.9 ) . 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducin
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1287
- current approval status
- not_reconciled
- duplicate text group
- dup-6b113f6c9f8db0b761f7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-4e47eaf166a384fb1502
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 1532
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1520
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1698
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1684
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1755
- end exclusive
- true
- exact text
- 1.1 Rheumatoid Arthritis HADLIMA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1487
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 16 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2088
- end exclusive
- true
- exact text
- symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and olde
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1556
- current approval status
- not_reconciled
- duplicate text group
- dup-9dfb612a893b17209b27
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-7eb82e8838ad3b18d254
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1848
- end exclusive
- true
- exact text
- methotrexate or other non-biologic disease-
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1805
- context exact
- HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1887
- end exclusive
- true
- exact text
- in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1785
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 1888
- end exclusive
- true
- exact text
- HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1756
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2290
- end exclusive
- true
- exact text
- patients with moderately to severely active rheumatoid arthritis. HADLIMA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HADLIMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and impro
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1689
- current approval status
- not_reconciled
- duplicate text group
- dup-bf91629d54d83cd64a78
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-bc78498534514f80be5e
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 1943
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1931
- qualifier mentions
- context exact
- ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2079
- end exclusive
- true
- exact text
- 2 years of age
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2065
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2090
- end exclusive
- true
- exact text
- 1.2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1889
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 18 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2353
- end exclusive
- true
- exact text
- 2 Juvenile Idiopathic Arthritis HADLIMA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HADLIMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1891
- current approval status
- not_reconciled
- duplicate text group
- dup-28f3fbd466ea106242ee
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-b6a056e6ef3a0b00e7b6
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- HADLIMA can be used alone or in combination with methotrexate.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2152
- end exclusive
- true
- exact text
- methotrexate
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2140
- context exact
- HADLIMA can be used alone or in combination with methotrexate.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2152
- end exclusive
- true
- exact text
- in combination with methotrexate
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2120
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2153
- end exclusive
- true
- exact text
- HADLIMA can be used alone or in combination with methotrexate.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2091
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2563
- end exclusive
- true
- exact text
- ng signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HADLIMA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HADLIMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondyli
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 1954
- current approval status
- not_reconciled
- duplicate text group
- dup-bc0f972ec141a529c7d9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-8f7c1539c616d6fc71fa
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 2198
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2186
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2330
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2316
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2363
- end exclusive
- true
- exact text
- 1.3 Psoriatic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2154
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 20 · unclassified context
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2633
- end exclusive
- true
- exact text
- tic Arthritis HADLIMA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HADLIMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of mod
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2164
- current approval status
- not_reconciled
- duplicate text group
- dup-6c4661399e3766c79391
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-3d2ee6b1b4a9a2f3b29a
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- HADLIMA can be used alone or in combination with non-biologic DMARDs.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2432
- end exclusive
- true
- exact text
- in combination with non-biologic DMARDs
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2393
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2433
- end exclusive
- true
- exact text
- HADLIMA can be used alone or in combination with non-biologic DMARDs.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2364
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 21 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2767
- end exclusive
- true
- exact text
- hibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HADLIMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HADLIMA i
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2234
- current approval status
- not_reconciled
- duplicate text group
- dup-5e03defc253aab605570
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-51a83b999d151ed64d31
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 2481
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2469
- qualifier mentions
- context exact
- tis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2531
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2517
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2567
- end exclusive
- true
- exact text
- 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2434
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 22 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2934
- end exclusive
- true
- exact text
- IMA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HADLIMA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has no
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2368
- current approval status
- not_reconciled
- duplicate text group
- dup-8559fe239c59b467ff28
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-826bde8e849122ce9346
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 2608
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2596
- qualifier mentions
- context exact
- eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2685
- end exclusive
- true
- exact text
- adults
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2679
- context exact
- moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2708
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2690
- context exact
- ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2723
- end exclusive
- true
- exact text
- 6 years of age
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2709
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2734
- end exclusive
- true
- exact text
- 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2568
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 23 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3067
- end exclusive
- true
- exact text
- h active ankylosing spondylitis. 1.5 Crohn’s Disease HADLIMA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Pla
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2535
- current approval status
- not_reconciled
- duplicate text group
- dup-91fd370ce058eb1a98d9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-2e5b69bb3101894ad870
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 2778
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2766
- qualifier mentions
- context exact
- ment of moderately to severely active ulcerative colitis in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2866
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2852
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 2867
- end exclusive
- true
- exact text
- 1.6 Ulcerative Colitis HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2735
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 24 · limitation of use
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 3259
- end exclusive
- true
- exact text
- disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HADLIMA is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2668
- current approval status
- not_reconciled
- duplicate text group
- dup-1894518de09029112caa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-4d0b88b455168c0586b1
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 3059
- end exclusive
- true
- exact text
- Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2868
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 25 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3509
- end exclusive
- true
- exact text
- tients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa HA
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 2860
- current approval status
- not_reconciled
- duplicate text group
- dup-17321c86d870cf7f3517
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-8a3bbf8ba0f12d3c398c
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 3101
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3089
- qualifier mentions
- context exact
- Plaque Psoriasis HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
- kind
- age
- polarity
- not_inferred
- span
- end
- 3137
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3123
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 3309
- end exclusive
- true
- exact text
- 1.7 Plaque Psoriasis HADLIMA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3060
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 26 · risk or warning
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 3677
- end exclusive
- true
- exact text
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis HADLIMA is indicated for the treatment of non-infecti
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3110
- current approval status
- not_reconciled
- duplicate text group
- dup-5dcc966c8bac5054750c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-19b3219a4a6fdf07609d
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 3477
- end exclusive
- true
- exact text
- HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] .
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3310
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 27 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3739
- end exclusive
- true
- exact text
- are medically less appropriate. HADLIMA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3278
- current approval status
- not_reconciled
- duplicate text group
- dup-30f6d90ae9173a62ff3e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-547cea0f2c2d1493394e
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 3527
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3515
- qualifier mentions
- context exact
- treatment of moderate to severe hidradenitis suppurativa in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3610
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3596
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 3611
- end exclusive
- true
- exact text
- 1.8 Hidradenitis Suppurativa HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3478
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 28 · positive indication candidate
- application numbers
- BLA761059
- brand names
- HADLIMA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3739
- end exclusive
- true
- exact text
- up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa HADLIMA is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3412
- current approval status
- not_reconciled
- duplicate text group
- dup-c92ceda2257e22d4b75c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-BWWD
- id
- ind-span-abe2d974dc7055d793a3
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- positive predicate support span
- end
- 3644
- end exclusive
- true
- exact text
- is indicated
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3632
- qualifier mentions
- context exact
- f non-infectious intermediate, posterior, and panuveitis in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3738
- end exclusive
- true
- exact text
- adult patients
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3724
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source defined aliases
- source span
- end
- 3739
- end exclusive
- true
- exact text
- 1.9 Uveitis HADLIMA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
- label id
- 6ac2e906-b32e-4c8e-909f-ff26b987d0c3
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c9f0352554fc653de79c34fbb1193a0e55cfcae9b8daec9331ff142271de409e
- start
- 3612
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%226ac2e906-b32e-4c8e-909f-ff26b987d0c3%22
- spl effective date
- 2026-05-14
- spl set id
- c361dd60-c88d-4f3c-b98c-79687bbc3450
- spl version
- 3
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Preserved source evidence · Not medical advice